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 Temocillin is a β-lactam increasingly used in serious infections caused by Enterobacteriaceae, 
including ESBLs and even some carbapenemase-producing strains, as an alternative to 
carbapenems (1-5).  
 Therefore, accuracy of in vitro minimal inhibitory concentration (MIC) values is of high importance in 
an era of antibiotic stewardship based on PK/PD. 
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 34 isolates were collected from respiratory samples isolated from ICU patients.  
 MIC of temocillin were determined in parallel by 3 methods:  
  E-test® (Biomérieux) 
  Vitek2® (Biomérieux)  
  BMD, following CLSI recommendations.  
 Since no EUCAST or CLSI breakpoint guidelines exist at this time, susceptibility to temocillin was 
determined according to breakpoints provided by BSAC (British Society for Antimicrobial 
Chemotherapy) in order to evaluate categorical agreement (S: MIC ≤ 8 mg/L; R: MIC > 8 mg/L) (6).  
 The production of ESBL or carbapenemase was screened according to the antibiotic susceptibility 
profile.  
 ESBL expression was confirmed by the double-disc synergy test. 
 Carbapenemase production was established by a colorimetric test detecting the carbapenem 
hydrolysis or using an immunochromatographic assay. 
  
 
Compared to BMD, Vitek2® seems to overestimate sensitivity and underestimate resistance, while E-test® seems to 
overestimate resistance, pleading for the use of BMD when evaluating susceptibility to temocillin. However, this study, 
which is currently enrolling more patients, will include more isolates in order to meet FDA criteria set out in Cumitech 
31A for validation of method comparison (7). 
Conclusions 
Introduction/Background 
 We aim to compare the performance of E-test® and Vitek2® vs. the standard broth microdilutition 





Isolates included:  
 Klebsiella pneumoniae (10/34; 29.4%), 
Escherichia coli (10/34; 29.4%), Serratia 
marcescens (6/34; 17.7%), others (8/34; 
23.5%).  
 Five (14.7%) were ESBL-producers.  
 None were carbapenemase-producers.  
 7/34 (20.6%) isolates were resistant to 
temocillin according to BMD method. 
 
  Both S Both R Concordant 
results 
R by the tested 
method and S by 
BMD  
S by the tested 
method and R by 
BMD  
E-test® 22/27 (81.5%) 6/7 (85.7%) 28/34 (82.4%) 5/27 (18.5%) 1/7 (14.3%) 
Vitek2® 25/27 (92.6%) 1/7 (14.3%) 26/34 (76.5%) 2/27 (7.4%) 6/7 (85.7%) 
Table 1. Agreement between methods 
Figure 1. Repartition of MIC values according to different 
MIC methods used 
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